Based on research from Brigham Young University and University of Utah, Sera has added $36m to its funding vault to drive commercialisation of its blood testing system PreTRM.
Sera Prognostics, US-based prenatal diagnostics technology developer based on research from Brigham Young University and University of Utah, collected $36m in a series D round yesterday co-led by investment firm Blue Ox Healthcare Partners.
Two unnamed healthcare companies co-led the round, which additionally included life sciences research company Laboratory Corporation of America (LabCorp), Domain Associates, InterWest Partners, Catalyst Health Ventures and Chione.
Founded in 2008, Sera Prognostics has created a blood testing system, PreTRM, that offers a personalised, early prediction of an expectant mother’s risk of giving birth prematurely or suffering from complications during pregnancy.
The latest round will enable Sera to bolster commercialisation efforts for PreTRM.
LabCorp previously led a $40m series C round in January 2017, investing alongside undisclosed existing shareholders.
Bill & Melinda Gates Foundation backed a $25m series B round in 2015 together with Osage University Partners, Chione, Domain Associates, InterWest Partners, Catalyst Health Ventures and UpStart Life Sciences Capital.
Sera had already closed a $19.3m series A round in 2011 co-led by InterWest Partners, Domain Associates and Catalyst Health Ventures, and with participation from Osage University Partners and UpStart Life Sciences Capital.
– A version of this article first appeared on our sister site, Global Corporate Venturing.
